DV
Therapeutic Areas
Avata Biosciences Pipeline
| Drug | Indication | Phase |
|---|---|---|
| AVAT-021 | Adult Focal Epilepsy | Phase 2 |
| AVAT-021 (Pediatric) | Pediatric Focal Epilepsy | Preclinical/Phase 1 |
| AVAT-022 | Pediatric Focal Epilepsy | Discovery/Preclinical |
| AVAT-031 | Schizophrenia | Discovery |
| AVAT-041 | Opioid Sparing/Addiction | Discovery |
Leadership Team at Avata Biosciences
JB
Julian Bryson
Executive Chairman & Cofounder
RH
Rupert Haynes
Chief Executive Officer & Cofounder
DA
Dr. Andrew Saich
Chief Medical Officer & Cofounder
GP
Grace Powell
Head of Regulatory Affairs
DC
Dr. Chris Hayes
Head of Intellectual Property
JG
Jim Gillespie
Program Director
DE
Dr. Emma Cheetham
Patent Portfolio Director